The active ingredient in popular weight-loss medications like Ozempic is showing early promise for treating alcohol use disorder, according to new research findings. A study indicates that the compound may help reduce alcohol consumption in people with obesity.

Meanwhile, consumer product companies are reporting unexpected market effects from the widespread adoption of GLP-1 drugs. Hershey Company has observed increased sales of gum and mint products, which executives attribute to users of weight-loss medications seeking breath freshening products.

The findings highlight the broader implications of GLP-1 drugs beyond their primary use for weight management and diabetes treatment. These medications, which include semaglutide-based products like Ozempic and Wegovy, have gained significant popularity among consumers seeking weight loss solutions.

Hershey CEO Kirk Tanner acknowledged the company is navigating the impact of weight-loss drugs on consumer behavior while also addressing challenges from stretched consumer spending. The chocolate maker is exploring opportunities to adapt to changing market conditions driven by these medications.

The research on alcohol use disorder treatment represents an expanding area of investigation for GLP-1 drugs, as scientists explore additional therapeutic applications beyond their established uses for diabetes and obesity management.